ArticlebioRxiv : the preprint server for biology2025
NASP functions in the cytoplasm to prevent histone H3 aggregation during early embryogenesis.
Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
6 authors.
Funding
Abstract
From their molecular birth until their incorporation into chromatin, histones are bound by specific chaperones that serve unique functions in histone trafficking, stability and chromatin deposition. The H3-specific chaperone NASP binds directly to H3 and is required to prevent degradation of soluble H3 in vivo. Where NASP functions and how NASP affects H3 dynamics and stability is unknown. Using the Drosophila early embryo as a model system to understand NASP function in vivo, we show that NASP does not directly affect H3 nuclear import or export rates. Rather, reduced H3 levels in NASP-deficient embryos indirectly affect nuclear import and the amount of H3 deposited into chromatin. Crucially, we find that cytoplasmic NASP prevents H3 aggregation in vivo and that H3 aggregation and degradation are developmentally separable events. Thus, we propose the main function of NASP in vivo is to prevent H3 aggregation, thereby indirectly protecting H3 from degradation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.